Rezolute Inc. highlighted its lead program, RZ358 (ersodetug), a fully human monoclonal antibody designed to treat hypoglycemia caused by hyperinsulinism by allosterically modulating the insulin receptor. The company discussed development across two indications—congenital hyperinsulinism and tumor hyperinsulinism—including Phase 2b RIZE data and Phase 3 sunRIZE study design and outcomes, and noted ongoing clinical and expanded access experience. Rezolute also referenced its cash position of $133 million with runway to mid-2027 and outlined upcoming milestones, including planned FDA engagement for congenital hyperinsulinism in Q1 2026 and expected topline data for tumor hyperinsulinism in the second half of 2026. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on February 18, 2026, and is solely responsible for the information contained therein.